Translate page

English English
en Englishbg Bulgarianzh-CN Chinese (Simplified)hr Croatiancs Czechda Danishnl Dutchfi Finnishfr Frenchde Germanel Greekiw Hebrewhi Hindiid Indonesianit Italianja Japaneseko Koreanmk Macedonianpl Polishpt Portuguesero Romanianru Russiansr Serbiansk Slovaksl Slovenianes Spanishsv Swedishth Thaitr Turkishvi Vietnamese

EHA 2018: Does IFN-alpha improve outcome of CML in the TKI era? (Franck E. Nicolini)

Presentations from the 23rd Congress of EHA 

 
EHA 2018 Nicolini


Does IFN-α improve outcome of CML in the TKI era?
Dr Franck-Emmanuel Nicolini, Centre Hospitalier Universitaire de Lyon, France 

  • LSC persistence on TKI
  • IFN-α anti-tumorigenic activities
  • IFN-α alone and CML: last clinical data
  • What do we know nowadays about the combination of IFN-α and TKI?
  • IFN-α alone as maintenance therapy?
  • Conclusions
 We are very grateful for the support of Brandcast media to produce these webstreams.

EHA 2018: Treatment options in resistant CML patients (Jane Apperley)

Presentations from the 23rd Congress of EHA 

We are pleased to make available a couple of presentations on various aspects of CML management that were first presented at the 23rd Congress of the European Hematology Association in Stockholm. Presentations include; treatment options in resistant CML patients, Does IFN-α improve outcome of CML in the TKI era? and TFR - a new goal for CP-CML patients?
 
EHA 2018 Apperley


Treatment options in resistant CML patients
Professor Jane Apperley, Imperial College London, UK 

  • Patient case history 2013 - 2017
  • ELN and NCCN definitions of response and failure
  • Outcome of 'real-life' 1st line imatinib by Sokol
  • Importance of ACA
  • ABL KD mutation sensitivity
  • CCyR rates for sequential use of NIL and DAS after IM failure
  • 3rd line therapy with Bosutinib
  • Relationship of line of therapy to efficacy for PON in 3rd-line vs. 4th line CML
  • SCT for CML: the EBMT score
We are very grateful for the support of Brandcast media to produce these webstreams.

Virtual Education Program - COLT Meeting 2017 (Session 4)

 

             

Naranie                       

       Dr Naranie Shanmuganathan

                         

 

 Session 4: CML related topics

  • Managing TKI toxicities 
    (Dr Naranie Shanmuganathan)

 

Virtual Education Program - COLT Meeting 2017 (Session 5)

 -- Virtual Education Program: 2017 Edition

 

Presentations from a CML Opinion Leader Meeting

We are pleased to make available a new series of presentations from the COLT Meeting 2017, a CML Opinion Leader Training that took place in Adelaide (Australia). Modules currently featured include; frontline CML, TKI resistance/failure, future directions for CML, CML related topics and the CML frontier - all presented by leaders in the field. 

Collage COLT 2017 Session 5

Prof. Timothy Hughes     Dr Agnes Yong

 

 

 
Session 5: The CML frontier
  • Making TFR mainstream 
    (Prof. Timothy Hughes)
  • The immunology of CML and immunomodulation
    (Dr Agnes Yong)

 

JGM 2017: Response to front-line imatinib treatment in children and adolescents with CML (Prof. Suttorp)

Presentations from the 19th John Goldman Conference on CML

We are pleased to make available a couple presentations recorded during the scientific sessions at the 19th Annual John Goldman Conference on CML in Estoril. Presentations currently featured include response to front-line imatinib treatment in children and adolescents and factors affecting adherence in CML and ways to improvement. More presentations will be made available over the next couple of weeks.
VEP Suttorp

Response to front-line imatinib treatment in children and adolescents with CML -
data from a large pediatric cohort
Meinolf Suttorp, University Hospital Dresden, Germany 

  • Study design
  • Hematological findings at diagnosis
  • Imatinib dose, monitoring, and methods
  • Cytogenetic response in patients with CML-CP
  • Molecular response in patients with CML-CP
  • Impairment of growth in pediatric patients on imatinib
  • Probability of PFS in patients diagnosed in CML-CP
  • Summary

JGM 2017: Factors influencing adherence in CML and ways to improvement (Jana Pelouchová)

Jana Pelouchova

 

 

  

         

 

Factors influencing adherence in CML and ways to improvement:
Results from a patient-driven survey of 2,546 patients in 63 countries
Jana Pelouchová, European Cancer Patient Coalition (ECPC), Czech Republic 

  • CML Advocates Network: Patients creating scientific evidence
  • Why this study?
  • Where are we now?
  • Truly global research: 2,546 patients from 63 countries
  • Validated adherence scales to classify patients into levels of adherence
  • Results on adherence levels
  • What can we do to drive adherence?
  • Conclusions